Lercanidipina Aurobindo (Lercanidipine Hydrochloride)

Lercanidipine is a dihydropyridine calcium‑channel blocker that selectively inhibits L‑type calcium channels in vascular smooth muscle. By reducing calcium influx, it causes arterial vasodilation, decreases peripheral vascular resistance, and consequently lowers systemic blood pressure.

The dosage of Lercanidipina Aurobindo is determined by the prescribing clinician based on the individual’s blood pressure response, age, renal and hepatic function, and concomitant therapies. The prescriber selects an appropriate starting dose and may adjust it during follow‑up visits.

Safety of lercanidipine during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine calcium‑channel blocker class and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother 24‑hour blood pressure control, while amlodipine is more widely used and has a longer market history. Choice depends on physician preference, patient response and tolerability.

Lercanidipina Aurobindo tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect from moisture and light. Do not store in areas of high humidity or extreme heat, and keep out of reach of children.

The product is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Although uncommon, serious adverse reactions may include severe hypotension, myocardial infarction, hepatic dysfunction, angioedema, and life‑threatening allergic responses. Patients should seek immediate medical attention if they experience symptoms such as fainting, chest pain, severe swelling, or difficulty breathing.

Individuals with known hypersensitivity to lercanidipine or any component of the formulation should avoid the product. Caution is also advised in patients with severe aortic stenosis, unstable angina, or those taking interacting medications that could cause excessive blood pressure lowering.